BCIC

[BCIC @BCICMedia]

🚀 2026 Biomedical Pitch Competition

Connecting biomedical startups with global investors & accelerators.

📅 Finals: May 2026
⏰ Apply by Feb 28, 2026
🧬 Open to biotech startups (concept → pre-IPO)

👉 Apply: https://t.co/CIMs26oh51

#BCIC #Biotech #investment #VC #Startups

[BCIC @BCICMedia]

Intel’s $20B stock sale 6x oversubscribed is a global capital land grab for AI infrastructure. The AI race moved from software hype to an all-out battle for hardware capacity. Wall St is betting big on a decentralized chip supply chain.

[BCIC @BCICMedia]

Cognition is eyeing a $40B valuation, up from $26B just a few months ago, with ARR forecasted to reach $1B. AI VC is changing fast, the story still matters, but real revenue and the ability to scale it are starting to separate the winners from the rest.

[BCIC @BCICMedia]

Bank of America is putting $250B behind U.S. infrastructure over the next 18 months, data centers, compute, chips, power and the grid. AI gets most of the attention, but all of it needs infrastructure behind it. The money is starting to follow.

[BCIC @BCICMedia]

NVIDIA is bringing Wall Street into AI, $500B+ in capital with Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR. This isn’t just about selling chips anymore, it’s about building the financial ecosystem around compute.

[BCIC @BCICMedia]

Moove raised $250M at a $2.1B valuation, The real story isn’t the funding it’s the infrastructure behind autonomous driving: fleets, charging, maintenance and operations, AI needs compute, autonomous mobility needs infrastructure, The Physical AI era is coming.

[BCIC @BCICMedia]

Promising update from Sana Biotechnology: its islet cell therapy UP421 produced insulin for 14 months in a Type 1 diabetes patient without immunosuppression.

Next up: IND for stem cell–derived SC451 and a planned Phase 1 trial in 2026. A potential step toward a functional cure.

[BCIC @BCICMedia]

Servier is acquiring Day One Biopharmaceuticals for $2.5B ($21.50/share) to strengthen its rare oncology portfolio.The deal brings Ojemda approved by the U.S. Food and Drug Administration in 2024 for pediatric low-grade glioma—alongside Servier’s Voranigo for IDH-mutant glioma

[BCIC @BCICMedia]

New biotech alert 🚀

Atrium Therapeutics has officially launched.

🔹 $270M cash
🔹 2 preclinical siRNA cardio programs
🔹 Led by former Avidity exec Kathleen Gallagher
Phase 1 for ATR-1072 (PRKAG2 syndrome) planned 2H this year. RNA cardiology is heating up. 💥

[BCIC @BCICMedia]

FDA win in CLL 🚨

AstraZeneca’s Calquence + Venclexta just became the first all-oral, fixed-duration (14-month) BTK regimen approved in the U.S. for 1L CLL/SLL.

Phase 3 (AMPLIFY):
• 35% ↓ risk of progression/death vs chemo
• Median PFS not reached
• 6% vs 14% deaths

[BCIC @BCICMedia]

Biotech IPO window reopening in Japan 🇯🇵🧬

Tokyo-based Innovacell plans to list Feb 24, pricing shares at ¥1,350 and aiming to raise ~¥14.2B (~$92M).

The cell therapy company is advancing ICEF15 (Phase 3) for urge fecal incontinence — positioning itself as a late-stage story.

[BCIC @BCICMedia]

Rare disease win: BridgeBio Pharma’s infigratinib hit in Phase 3 (PROPEL 3) for achondroplasia.

+2.1 cm/yr vs placebo, met proportionality endpoints, clean safety (no serious tox/discontinuations). Shares +15%.

NDA planned 2H. Would compete with Voxzogo. #biotech #raredisease

[BCIC @BCICMedia]

Bayer’s Phase 3 OCEANIC-Stroke trial shows Factor XIa inhibitor asundexian cut recurrent stroke risk by 26% without increasing major bleeding. In >12,000 post-stroke/TIA patients, bleeding rates were similar to placebo which is renewing optimism for safer next-gen blood thinners.

[BCIC @BCICMedia]

Biogen is betting on a high-dose Spinraza to revive its SMA franchise 📈

Spinraza sales fell to $1.55B in 2025 amid pressure from Roche’s Evrysdi, but early uptake of high-dose Spinraza in Japan/Europe looks stronger than expected. FDA decision due April 3.

[BCIC @BCICMedia]

Moderna is out-licensing global commercial rights to its rare disease asset mRNA-3927 (propionic acidemia) to Italy’s Recordati. Deal includes $50M upfront, up to $110M in milestones, plus royalties. Some analysts called the terms “modest.” Shares dipped slightly. 🧬💊

[BCIC @BCICMedia]

Chugai has dropped BRY10, a Phase 1 chronic disease antibody that used its in-house AI platform Malexa during lead optimization.

They say the decision was based on data, not concerns with the AI, and Malexa will continue to be used across other antibody programs as Chugai.

[BCIC @BCICMedia]

AstraZeneca doubles down on obesity 🌍
$1.2B upfront to CSPC Pharma for ex-China rights to an 8-asset, once-monthly weight management portfolio—led by a long-acting GLP-1/GIP agonist heading into Ph1.
Total deal: up to $3.5B in dev milestones + ~$14B in sales milestones.

[BCIC @BCICMedia]

New JCVI spinoff Diploid Genomics is blending AI, long-read sequencing (PacBio + Oxford Nanopore), advanced imaging, and health data to deliver more precise genomic insights. With its own clinical-grade sequencing center coming in San Diego.

[BCIC @BCICMedia]

BMS is teaming up with Janux Therapeutics in a deal worth up to $850M to advance a tumor-activated T cell therapy for solid tumors.

The approach keeps T cell engagement “masked” until the drug reaches the tumor, aiming to reduce systemic toxicity seen with classic T cell engager

[BCIC @BCICMedia]

Health AI startup OpenEvidence raised $250M at $12B valuation, doubling its value in a year. Used by 18M clinicians, the company says investors are betting not just on ads but on its ambition to build "medical superintelligence" that could transform care.

[BCIC @BCICMedia]

AstraZeneca has struck a $630M deal to buy the remaining China rights to C-CAR031, an armored GPC3-targeting CAR-T originally partnered with AbelZeta Pharma. C-CAR031 is based on AZD5851 platform and uses a TGFβRII dominant-negative armoring approach to boost CAR-T function.